Jump Financial LLC Has $369,000 Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)

Jump Financial LLC lifted its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 152.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,500 shares of the company’s stock after purchasing an additional 29,908 shares during the period. Jump Financial LLC’s holdings in Acelyrin were worth $369,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Amalgamated Bank bought a new stake in Acelyrin during the third quarter worth $44,000. New York State Common Retirement Fund increased its position in Acelyrin by 84.4% during the fourth quarter. New York State Common Retirement Fund now owns 13,181 shares of the company’s stock worth $98,000 after acquiring an additional 6,032 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Acelyrin by 608.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,716 shares of the company’s stock valued at $80,000 after buying an additional 9,203 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Acelyrin in the fourth quarter worth $84,000. Finally, SG Americas Securities LLC acquired a new position in shares of Acelyrin in the 4th quarter valued at approximately $110,000. 87.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

SLRN has been the topic of a number of research analyst reports. HC Wainwright raised their price target on shares of Acelyrin from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company lifted their price objective on Acelyrin from $11.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 21st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $22.00.

Acelyrin Trading Down 2.1 %

Shares of Acelyrin stock opened at $4.13 on Friday. Acelyrin, Inc. has a 12-month low of $4.05 and a 12-month high of $29.88. The stock has a fifty day simple moving average of $5.41 and a 200 day simple moving average of $6.88.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.25. On average, research analysts anticipate that Acelyrin, Inc. will post -3.87 earnings per share for the current year.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.